Syros Pharmaceuticals announced that its phase 3 trial of tamibarotene in combination with azacitidine did not meet the primary endpoint for the treatment of myelodysplastic syndrome.
AT-02 is a fusion protein of humanized immunoglobulin G1 with a pan amyloid-reactive peptide that facilitates binding of the antibody to amyloid deposits and subsequent removal. The Food and Drug ...
Spreading medical misinformation to the public and providing misinformation to patients receiving treatment were among the least common reasons for discipline. A large study suggests that, across the ...
(HealthDay News) — Virtual yoga classes may be a feasible, safe, and effective treatment option for chronic low back pain (CLBP), according to a study published online Nov. 1 in JAMA Network Open.
The Horizon® 3.0 Inspire has a compact design allowing for easier portability. The Food and Drug Administration (FDA) has cleared Magstim’s Horizon ® 3.0 Inspire for the treatment of major depressive ...
Researchers emulated target trials comparing recurrence of nephrolithiasis among patients with preexisting nephrolithiasis initiating SGLT-2 inhibitors vs an active comparator. (HealthDay News) — For ...
The Food and Drug Administration (FDA) has accepted for review the resubmitted Biologics License Application (BLA) for prademagene zamikeracel for the treatment of recessive dystrophic epidermolysis ...
GNSC-001 is an investigational, adeno-associated virus gene therapy expressing an optimized form of IL-1Ra. The Food and Drug Administration (FDA) has granted Fast Track designation to GNSC-001 for ...